Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Critical Reviews in Oncology/Hematology|May 14, 2005
Decision making process in oncology practice: is the information available and what should it consist of?Jean Trédaniel, Jean-Yves Blay, François Goldwasser, et al.
International Journal of Breast Cancer|June 14, 2013
Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 StudyFrançois-Clément Bidard, Lisa Belin, Suzette Delaloge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trialJean-Yves Pierga, François-Clément Bidard, Claire Mathiot, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patientsOdile Cohen-Haguenauer, Bruno Péault, Cécile Bauche, et al.
European Journal of Radiology|July 3, 2014
¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancerDavid Groheux, Elif Hindié, Michel Marty, et al.
Breast (Edinburgh, Scotland)|March 29, 2014
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) studyPatrick Neven, Christos Markopoulos, Minna Tanner, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2014
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancerDavid Groheux, Elif Hindié, Sylvie Giacchetti, et al.
American Journal of Clinical Oncology|June 3, 2009
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancerCarole Perez-Ellis, Anthony Goncalves, Jocelyne Jacquemier, et al.
Breast Cancer Research and Treatment|May 19, 2010
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patientsJean-Yves Pierga, Suzette Delaloge, Marc Espié, et al.
Oncogene|October 19, 2002
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancerElizabeth Turpin, Ivan Bièche, Philippe Bertheau, et al.
Pageof 6